{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:36:29Z","timestamp":1760146589153,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJNS"],"abstract":"<jats:p>The California Genetic Disease Screening Program (GDSP) employs a fixed immunoreactive trypsinogen (IRT) cutoff followed by molecular testing to screen newborns for cystic fibrosis (CF). The cutoffs approximate a 1.6% yearly IRT screen-positive rate; however, seasonal variation in IRT population means has led us to develop a model to establish fixed IRT cutoffs that anticipate seasonal variation and minimize missed cases below cutoff. We utilized an ARIMA model to fit monthly IRT screen-positive percentiles and estimated regular seasonal expectations. We established a retrospective cohort followed for at least 1.5 years to capture missed false-negative CF cases. We compared missed CF cases identified by seasonal cutoffs vs. floating cutoffs. GDSP screened 7,410,003 newborns, from July 2007 to December 2022, and missed 36 CF cases below the fixed cutoff; five of the 36 were within 3 ng\/mL below the cutoff. There was a regular, seasonal cycle that varied from 1.4% in summer to 1.8% in winter. We would have missed 59 CF cases using a 1.6% daily floating cutoff. California would need to use a 4% daily floating cutoff to improve our current detection rate, which would double the number of specimens sent for costly molecular analysis.<\/jats:p>","DOI":"10.3390\/ijns10040076","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:07:32Z","timestamp":1732277252000},"page":"76","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystic Fibrosis Screening Efficacy and Seasonal Variation in California: 15-Year Comparison of IRT Cutoffs Versus Daily Percentile for First-Tier Testing"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6191-8179","authenticated-orcid":false,"given":"Stanley","family":"Sciortino","sequence":"first","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Graham","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Bishop","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7916-8185","authenticated-orcid":false,"given":"Jamie","family":"Matteson","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Carter","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy H.","family":"Wu","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Genetic Disease Screening Program, California Department of Public Health, Richmond, CA 94804, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1542\/peds.2015-0811","article-title":"Newborn Screening for Cystic Fibrosis in California","volume":"136","author":"Kharrazi","year":"2015","journal-title":"Pediatrics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ppul.21330","article-title":"Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening","volume":"46","author":"Korzeniewski","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-015-2616-3","article-title":"Screening for cystic fibrosis in New York State: Considerations for algorithm improvements","volume":"175","author":"Kay","year":"2016","journal-title":"Eur. J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1542\/peds.2008-1681","article-title":"Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen","volume":"123","author":"Kloosterboer","year":"2009","journal-title":"Pediatrics"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Maier, P., Jeyaweerasinkam, S., Eberhard, J., Soueidan, L., H\u00e4mmerling, S., Kohlm\u00fcller, D., Feyh, P., Gramer, G., Garbade, S.F., and Hoffmann, G.F. (2024). Influence of Season, Storage Temperature and Time of Sample Collection in Pancreatitis-Associated Protein-Based Algorithms for Newborn Screening for Cystic Fibrosis. Int. J. Neonatal Screen., 10.","DOI":"10.3390\/ijns10010005"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kharrazi, M., Sacramento, C., Comeau, A., Hale, J., Caggana, M., Kay, D., Lee, R., Reilly, B., Thompson, J., and Nasr, S. (2022). Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8040058"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sicko, R.J., Stevens, C.F., Hughes, E.E., Leisner, M., Ling, H., Saavedra-Matiz, C.A., Caggana, M., and Kay, D.M. (2021). Validation of a Custom Next-Generation Sequencing Assay for Cystic Fibrosis Newborn Screening. Int. J. Neonatal Screen., 7.","DOI":"10.3390\/ijns7040073"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpeds.2016.03.046","article-title":"Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis","volume":"175","author":"Sontag","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ymgme.2021.08.005","article-title":"Improving outcomes for Colorado\u2019s IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs","volume":"134","author":"Martiniano","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e20182300","DOI":"10.1542\/peds.2018-2300","article-title":"Newborn Screening for Severe Combined Immunodeficiency and T-cell Lymphopenia in California, 2010\u20132017","volume":"143","author":"Amatuni","year":"2019","journal-title":"Pediatrics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jaci.2019.05.038","article-title":"Reference intervals for lymphocyte subsets in preterm and term neonates without immune defects","volume":"144","author":"Amatuni","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/ppul.21509","article-title":"Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening","volume":"46","author":"Rock","year":"2011","journal-title":"Pediatr. Pulmonol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/ppul.27155","article-title":"Improved detection of cystic fibrosis by the California Newborn Screening Program for all races and ethnicities","volume":"59","author":"McGarry","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Matteson, J., Sciortino, S., Feuchtbaum, L., Bishop, T., Olney, R.S., and Tang, H. (2021). Adrenoleukodystrophy Newborn Screening in California Since 2016: Programmatic Outcomes and Follow-Up. Int. J. Neonatal. Screen., 7.","DOI":"10.3390\/ijns7020022"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"114287","DOI":"10.1016\/j.jpeds.2024.114287","article-title":"Diagnostic Transitions of Cystic Fibrosis and CRMS Compared After 12 Years of Newborn Screening in California","volume":"276","author":"Sciortino","year":"2024","journal-title":"J. Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bianchimani, C., Dolce, D., Centrone, C., Campana, S., Ravenni, N., Orioli, T., Camera, E., Mergni, G., Fevola, C., and Bonomi, P. (2022). Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)\/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience. Int. J. Neonatal Screen., 8.","DOI":"10.3390\/ijns8030046"}],"container-title":["International Journal of Neonatal Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/4\/76\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:37:50Z","timestamp":1760114270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2409-515X\/10\/4\/76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["ijns10040076"],"URL":"https:\/\/doi.org\/10.3390\/ijns10040076","relation":{},"ISSN":["2409-515X"],"issn-type":[{"type":"electronic","value":"2409-515X"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}